```json
{
"content": [
{
"type": "paragraph",
"content": "Community-acquired bacterial pneumonia (CABP) is a significant infectious disease acquired outside healthcare settings, representing a critical public health challenge. The CABP market size is driven by the rising prevalence of antibiotic-resistant pathogens, aging populations, and advancements in diagnostic technologies. This market forecast underscores the industry expansion potential, with key stakeholders focusing on innovation to address unmet clinical needs."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Antibiotics", "Diagnostics", "Supportive Care"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[3500, 3700, 3900, 4100, 4300, 4500, 4700, 4900, 5100, 5300, 5500, 5700, 5900], // Antibiotics
[1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400], // Diagnostics
[800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400] // Supportive Care
]
}
},
{
"type": "paragraph",
"content": "The CABP market is projected to grow at a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033, with the global market size estimated at $9.6 billion in 2025, reflecting a robust growth outlook. Key macro drivers include increasing healthcare expenditure in emerging economies, regulatory incentives for novel antibiotic development, and the shift toward rapid molecular diagnostics to combat antimicrobial resistance. North America remains the largest regional market due to high disease incidence and advanced healthcare infrastructure, while the Asia-Pacific region is the fastest-growing market, fueled by urbanization and expanding access to medical facilities. Strategic partnerships between pharmaceutical firms and diagnostics companies further underscore the industry’s transformation toward precision therapies."
}
]
}
```
